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Abstract
Background: Quality of life (QoL) refers to the physical, psychological, social and medical aspects of life that are
influenced by health status and function. The purpose of this study was to measure the self-perceived health status
among the elderly population across Europe in different stages of Chronic Kidney Disease (CKD).
Methods: Our series consisted of 2255 community-dwelling older adults enrolled in the Screening for Chronic
Kidney Disease (CKD) among Older People across Europe (SCOPE) study. All patients underwent a comprehensive
geriatric assessment (CGA), including included demographics, clinical and physical assessment, number of
medications taken, family arrangement, Geriatric Depression Scale (GDS), Cumulative Illness Rating Scale, History of
falls, Lower urinary tract symptoms, and Short Physical Performance Battery (SPPB). Estimated glomerular filtration
rate (eGFR) was calculated by Berlin Initiative Study (BIS) equation. Quality of life was assessed by Euro Qol
questionnaire (Euro-Qol 5D) and EQ-Visual Analogue Scale (EQ-VAS). The association between CKD (eGFR < 60, < 45ml
or < 30ml/min/1.73m2) and low EQoL-VAS was investigated by multivariable logistic regression models.
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Results: CKD was found to be significantly associated with low EQoL-VAS in crude analysis (OR = 1.47, 95%CI = 1.16–
1.85 for eGFR< 60; OR = 1.38, 95%CI = 1.08–1.77 for eGFR< 45; OR = 1.57, 95%CI = 1.01–2.44). Such association was no
longer significant only when adjusting for SPPB (OR = 1.20, 95%CI = 0.93–1.56 for eGFR< 60; OR = 0.87, 95%CI = 0.64–
1.18 for eGFR< 45; OR = 0.84, 95%CI = 0.50–1.42), CIRS and polypharmacy (OR = 1.16, 95%CI = 0.90–1.50 for eGFR< 60;
OR = 0.86, 95%CI = 0.64–1.16 for eGFR< 45; OR = 1.11, 95%CI = 0.69–1.80) or diabetes, hypertension and chronic
obstructive pulmonary disease (OR = 1.28, 95%CI = 0.99–1.64 for eGFR< 60; OR = 1.16, 95%CI = 0.88–1.52 for eGFR< 45;
OR = 1.47, 95%CI = 0.92–2.34). The association between CKD and low EQoL-VAS was confirmed in all remaining
multivariable models.
Conclusions: CKD may significantly affect QoL in community-dwelling older adults. Physical performance,
polypharmacy, diabetes, hypertension and COPD may affect such association, which suggests that the impact of CKD
on QoL is likely multifactorial and partly mediated by co-occurrent conditions/risk factors.
Keywords: Quality of life, Chronic kidney disease, Old adults
Background
The importance of Quality of life (QoL) in old age was
acknowledged in the WHO report on healthy aging
2015 [1]. However, rising life expectancy worldwide is
not limited to the healthy population, but also affects
subpopulations with a history of disease, which contrib-
ute to make QoL a relevant outcome in terms of public
health among older people [2].
QoL is basically a subjective condition that expresses
how people are satisfied with their life and the degree of
wellbeing and happiness they feel [3]. Health-related QoL
refers to the physical, psychological, social, spiritual as-
pects of QoL that are influenced by health and health-
related events such as diseases and their treatments [4, 5].
Chronic kidney disease (CKD) is among chronic dis-
eases significantly affecting QoL among older people.
Besides exerting a major effect on global health, either as
a risk factor for morbidity and mortality or by causing
cardiovascular disease [6], the burden of CKD in older
people is also related to its complications, including im-
paired physical function [7, 8], frailty [9, 10], cognitive
impairment [11], vision impairment [12], malnutrition
[13], and sarcopenia [14]. All the above may influence
QoL of older adults.
Most studies showed that severe CKD and dialysis
have negative impact on Health Related QoL [15, 16].
However, due to the slow and unpredictable nature of
CKD trajectories, earlier CKD stages (e.g. stage 3a and
3b) may also significantly affect Health Related QoL
[17]. The few studies investigating the impact of early
stages of CKD on QoL show that QoL may be poorer
than that of the general population, but better than for
CKD patients on dialysis [18, 19]. In a recent systematic
review, Yapa et al. [20] showed that health-related QoL
may worsen when CKD symptoms (e.g. fatigue, exhaus-
tion and drowsiness) appear.
The objective of this cross-sectional study was to in-
vestigate the QoL among older adults across Europe in
early stages of CKD, in order to identify factors poten-
tially influencing the relationship between kidney func-
tion and QoL.
Methods
Study design and participants
The SCOPE study (European Grant Agreement no.
436849), is a multicenter prospective cohort study in-
volving patients older than 75 years attending geriatric
and nephrology outpatient services in participating insti-
tutions in Austria, Germany, Israel, Italy, the
Netherlands, Poland and Spain. Only people aged 75 or
more were asked to participate because of the high
prevalence of CKD in this population [21, 22]. Methods
of the SCOPE study have been extensively described
elsewhere [23]. Briefly, all patients attending the out-
patient services at participating centers from August
2016 to August 2018 were asked to participate. Only pa-
tients signing a written informed consent entered the
study. Age greater or equal to 75 years was the only in-
clusion criteria, the exclusion criteria were: end-stage
renal disease or dialysis at time of enrollment; history of
solid organ or bone marrow transplantation; active ma-
lignancy within 24months prior to screening or meta-
static cancer; life expectancy less than 6 months (based
on the judgment of the study physician after careful
medical history collection and diagnoses emerging from
examination of clinical documentation exhibited); severe
cognitive impairment (Mini Mental State Examination <
10); any medical or other reason (e.g. known or sus-
pected patients’ inability to comply with the protocol
procedure) in the judgement of the investigators, that
the patient was unsuitable for the study; unwilling to
provide consent and limited possibility to attend follow-
up visits. Enrolled patients underwent an extensive as-
sessment including: demographic data, socioeconomic
status, physical examination, comprehensive geriatric as-
sessment, bioimpedance analysis, diagnoses (clinical
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history and assessment of clinical documentation exhib-
ited by patients and/or caregivers), quality of life, physical
performance, overall comorbidity and blood and urine
sampling. Patients were followed-up for 24-months as
previously described [23]. The study protocol was ap-
proved by ethics committees at all participating institu-
tions, and complies with the Declaration of Helsinki and
Good Clinical Practice Guidelines. The study was regis-
tered at ClinicalTrials.gov (NCT02691546). Only baseline
data was used in the present study.
Overall, 2461 patients were initially enrolled in the
study; 206 patients were excluded because of incomplete
baseline data, thus leaving a final sample of 2255 partici-
pants to be included in the present analysis.
Study variables
QoL was assessed by EQ-Visual Analogue Scale (EQoL-
VAS), that is part of the Euro-Quality of Life 5D (Euro-
Qol 5D) [24–26]. The EQ-VAS asks participants to indi-
cate their overall health on a vertical visual analogue
scale, ranging from 0 “worst possible” to 100 “best pos-
sible” health. The Euro-Qol 5D is a standardized instru-
ment for measuring generic health rated QoL measure
with one question on five different dimensions that in-
clude mobility, self-care, usual activities, pain/discom-
fort, and anxiety/depression. The answers given to Euro-
QoL 5D are scored from 1 “I have no problems … “ for
perfect health to 5 “I am unable to …. “ for bad health
status. The 5-digit numbers for the five dimensions are
combined and describe the patient’s health state. The
Euro-Qol 5D and EQoL-VAS was formerly validated in
several different settings and clinical conditions [27–30].
Estimated glomerular filtration rate (eGFR) was calcu-
lated by Berlin Initiative Study (BIS) equation [31], and
categorized as < 60, < 45 or < 30ml/min/1.73m2.
Other variables included in the present study were:
demographics, body mass index (BMI), number of dis-
eases and medications taken, family arrangements; Basic
(ADL) and Instrumental Activities of Daily Living
(IADL) [32, 33]; Mini Mental State Exam (MMSE) [34];
15-items Geriatric Depression Scale, GDS [35]; Cumula-
tive Illness Rating Scale, CIRS [36]; History of falls;
Lower urinary tract symptoms, LUTS [37]; hand grip
strength [38]; Short Physical Performance Battery, SPPB
[39]. Selected diagnoses, including diabetes, hyperten-
sion, stroke, hip fractures, chronic obstructive pulmon-
ary disease, osteoporosis, Parkinson’s disease and anemia
were also considered as potential confounders.
Statistical analysis
Descriptive analyses of patients grouped according to
EQoL-VAS (low EQoL-VAS, 0–50, intermediate EQoL-
VAS, 51–75, and high EQoL-VAS, 75–100) were pre-
sented. The chi-square test was used for categorical
variables and ANOVA one-way test for continuous ones.
Post-hoc analysis for multiple comparisons was carried
out by Bonferroni correction for continuous variables
and by Dunn’s test for categorical ones. Therefore, mul-
tivariable logistic regression models were built to investi-
gate the association between CKD (eGFR < 60, < 45 or <
30ml/min/1.73m2) and low EQoL-VAS. Logistic regres-
sion models were as follows: crude (model 1), adjusted
for age and gender (model 2), furtherly adjusted by add-
ing family arrangement (i.e., being widow) (model 3),
SPPB (model 4), falls (model 5); mood status i.e., GDS >
5 (model 6), Cumulative Illness Rating Score and num-
ber of medications≥5 (model 7), LUTS (model 8), co-
morbidities (models 9 and 10), and anemia (model 11).
All statistical analyses were performed with SPSS statis-
tical software package version 24 (SPSS Inc., Chicago,
IL, USA). Statistical significance was set at P < 0.05.
Results
Table 1 shows that 984 out of 2255 participants (43.6%)
reported high EQoL-VAS, and 487 (21.6%) reported low
EQoL-VAS. More than half (55.96%) were married or
lived with a partner, 33.7% were widowed, 5.4% were
single and 24.4% lived alone. Older adults with low
EQoL-VAS (0–50) were more frequently women, single,
and widowed, and had lower education compared to
those with intermediate and with high EQoL-VAS
(Table 1).
Table 2 shows that eGFR was lower and the preva-
lence of CKD was higher among patients with low
EQoL-VAS, whatever was the eGFR threshold used.
Polypharmacy was also highly prevalent among patients
with low EQoL-VAS, who also exhibited higher average
CIRS score, greater prevalence of (LUTS) and comorbid-
ities and lower hemoglobin values (Table 2).
In regard to physical and emotional status, SPPB
scores and hand grip strength were lower and the preva-
lence of ADL/IADL dependency depression, cognitive
impairment and history of falls was higher (Table 3).
In logistic regression analyses (Table 4), CKD was sig-
nificantly associated with the outcome independent of
the eGFR threshold considered in the analysis. After
adjusting for age, sex, being widowed, history of falls,
GDS > 5, LUTS, stroke, hip fracture, Parkinson’s disease,
and anemia the association between eGFR and low
EQoL-VAS remained substantially unchanged (Table 4).
When we adjusted for SPPB (model 4), the association
between eGFR and the outcome was no longer signifi-
cant. Indeed, SPPB score qualified as a significant nega-
tive correlate of low EQoL-VAS (OR = 0.72; 95%CI =
0.69–0.76 in the eGFR< 60 analysis, OR = 0.72; 95%CI =
0.68–0.75 in the GFR < 45 analysis and OR = 0.72;
95%CI = 0.68–0.75 in the GFR < 30 analysis). Similarly,
CIRS (OR = 1.10; 95%CI = 1.07–1.13 in the eGFR< 60
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analysis, OR = 1.11; 95%CI = 1.01–1.14 in the GFR < 45
analysis and OR = 1.10; 95%CI = 1.07–1.14 in the GFR <
30 analysis) and number of medications (OR = 1.98;
95%CI = 1.49–2.62 for eGFR< 60 analysis, OR = 2.01;
95%CI = 1.51–2.66 in the GFR < 45 analysis and OR =
1.99; 95%CI = 1.50–2.64 respectively in the GFR < 30
analysis) were significantly associated with the study out-
come in model 7. Diabetes (OR = 1.42; 95%CI = 1.09–
1.85 in eGFR< 60 analysis, OR = 1.40; 95%CI = 1.07–1.84
in eGFR< 45 analysis and OR = 1.42; 95%CI = 1.09–1.86
in eGFR< 30 analysis), hypertension (OR = 1.83; 95%CI =
1.36–2.45 in eGFR< 60 analysis, OR = 1.87; 95%CI =
1.40–2.51 in eGFR< 45 analysis and OR = 1.86; 95%CI =
1.39–2.49 in eGFR< 30 analysis), and chronic obstructive
pulmonary disease (OR = 1.99; 95%CI = 1.41–2.82 in
eGFR< 60 analysis, OR = 2.01; 95%CI = 1.43–2.84 in
eGFR< 45 analysis and OR = 2.03; 95%CI = 1.44–2.87 in
eGFR< 30 analysis) also qualified as significant correlates
of low EQoL-VAS in model 9.
Discussion
The main finding of the present study is the association
between CKD and EQoL-VAS among older community-
dwelling people free from end-stage renal disease. Inter-
estingly, such association was confirmed with all eGFR
thresholds used (namely, stages 3a, 3b and 4). Thus, our
results add to the present knowledge by demonstrating
that early stages of CKD may significantly affect QoL
among older people.
Former studies clearly showed that end-stage renal
disease and dialysis are associated with low QoL [15, 16,
40, 41], and few studies reported that even early stages
of CKD may significantly affect QoL [17–20]. Our find-
ings are clearly different from that reported in a recent
cross-sectional analysis of the Irish Longitudinal Study
on Ageing showing that creatinine-based eGFR may
contribute little to QoL [42]. However, difference in age
of the enrolled populations likely account for this appar-
ent discrepancy. Indeed, only people aged 75 or more
were enrolled in the present study, while people enrolled
in the Irish study were younger (median age 61 years,
interquartile range 55–68) [42]. Thus, in the light of re-
sults from the present study and the above evidence, the
need of a patient-centered approach including universal
outcomes to CKD care among older people [43] could
be further suggested.
Main mechanisms linking CKD to QoL among older
people are likely linked to the complex profile of older
patients with CKD, which is known to be characterized
by impaired physical function [7, 8], frailty [9, 10], cogni-
tive impairment [11], vision impairment [12], malnutri-
tion [13], and sarcopenia [14]. The finding that selected
variable, such as physical performance, comorbidity and
polypharmacy, may significantly affect the relationship
between CKD and QoL is in keeping with such inter-
pretation. Former studies showed that reduced renal
function may be associated with poorer physical per-
formance in older patients [7], and impaired SPPB con-
tributes to describe the profile of older CKD patients
Table 1 Sociodemographic characteristics, according to EQoL-VAS category
Variable All participants
(n = 2255)
Group A Low EQoL-
VAS 0–50 (n = 487)
Group B Intermediate EQoL-
VAS 51–75 (n = 784)
Group C High EQoL-VAS
76–100 (n = 984)
p-value post hoc
Euro QoL questionnaire
(Euro-Qol 5D)
7.0 (4.0) 10.0 (5.0) 8.0 (4.0) 6.0 (3.0) < 0.001 a vs. b
a vs. c
b vs. c
Age (years) 79.5 (5.9) 80.0 (6.4) 79.5 (6.0) 79.2 (5.3) 0.009 a vs. c
Sex: female 1255 (55.7) 332 (68.2) 423 (54.0) 500 (50.8) < 0.001 a vs. b
a vs. c
b vs. c
Body mass index, BMI (kg/m2) 27.3 (5.7) 28.3 (6.1) 27.6 (5.9) 26.7 (5.3) < 0.001 a vs. c
b vs. c
Marital status
Single 121 (5.4) 35 (7.2) 40 (5.1) 46 (4.7) < 0.001 a vs. b
Married/ living with a
partner
1253 (55.6) 227(46.6) 439(56.0) 587 (59.7) a vs. c
Separated/divorced 120 (5.3) 31 (6.4) 47 (6.0) 42 (4.3)
Widowed 761 (33.7) 194 (39.8) 258 (32.9) 309 (31.4)
Education (years) 11.0 (7.0) 10.0 (5.0) 12.0 (7.0) 12.0 (7.0) < 0.001 a vs. b
a vs. c
NOTE. Values are mean ± SD for continuous normal distributions, n (%) for categorical variables, and median (interquartile range) for not normal distributions
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with increased risk of death [44]. Additionally, besides
confirming the impact of physical performance on QoL
[45], our study also showed that the average difference
across QoL groups observed in our study in regards to
SPPB score was clearly higher compared to minimum
clinically meaningful difference (i.e. 0.5 points) [46].
These findings further sustain the need of developing ex-
ercise interventions to improve physical performance
among CKD patients to counteract deterioration of QoL
[47, 48].
Overall comorbidity (i.e. CIRS score) and selected
diagnoses (i.e. diabetes, hypertension and chronic
Table 2 Clinical (Medical conditions) and laboratory parameters according to the EQoL-VAS category presented as N (%)
Variable All participants
(n = 2255)
Group A Low EQoL-VAS
(0–50) (n = 487)
Group B Intermediate EQoL-
VAS (51–75) (n = 784)
Group C High EQoL-VAS
(76–100) (n = 984)
p-value post hoc
eGFR, ml/min/1.73m2 54.2 (19.6) 53.2 (19.7) 54.1 (21.2) 55.7 (18.4) 0.005 a vs. c
< 60 1423 (63.1) 336 (69.0) 494 (63.0) 593 (60.3) 0.005 a vs. b
a vs. c
b vs. c
< 45 560 (24.8) 137 (28.1) 206 (26.3) 217 (22.1) 0.020 a vs. c
b vs. c
< 30 141 (6.3) 37 (7.6) 55 (7.0) 49 (5.0) 0.082
Diabetes 568 (25.2) 137 (28.1) 225 (28.7) 206 (21) < 0.001 a vs. b
a vs. c
b vs. c
Hypertension 1732 (76.8) 409 (84.0) 625 (79.7) 698 (70.9) < 0.001 a vs. b
a vs. c b
vs. c
Stroke 131 (5.8) 44 (9.0) 50 (6.4) 37 (3.8) < 0.001 a vs. b
a vs. c b
vs. c
Hip Fractures 111 (4.9) 36 (7.4) 44 (5.6) 31 (3.2) 0.001 a vs. b
a vs. c b
vs. c
Chronic obstructive
pulmonary disease (COPD)
267 (11.8) 76 (15.6) 99 (12.6) 92 (9.3) 0.002 a vs. b
a vs. c
b vs. c
Osteoporosis 688 (30.5) 186 (38.2) 252 (32.1) 250 (25.4) < 0.001 a vs. b
a vs. c
b vs. c
Parkinson’s disease 45 (2.0) 22 (4.5) 11 (1.4) 12 (1.2) < 0.001 a vs. b
a vs. c
Anemia 477 (21.2) 137 (28.1) 156 (19.9) 184 (18.7) < 0.001 a vs. b
a vs. c
Cumulative Illness Rating
Score (CIRS)
8.0 (6.0) 9.0 (7.0) 8.0 (7.0) 7.0 (6.0) < 0.001 a vs. b
a vs. c b
vs. c
Take ≥5 current
medications
1509 (66.9) 389 (79.9) 554 (70.7) 566 (57.5) < 0.001 a vs. b
a vs. c b
vs. c
Lower urinary tract
symptoms (LUTS)
653 (29.0) 173 (35.5) 257 (32.8) 223 (22.7) < 0.001 a vs. b
a vs. c
b vs. c
Hemoglobin (Hb) 13.5 ± 1.9 13.1 ± 1.5 13.5 ± 1.4 13.7 ± 1.4 < 0.001 a vs. c
NOTE. Values are mean ± SD for continuous normal distributions, n (%) for categorical variables, and median (interquartile range) for not normal distributions
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Table 3 Physical, cognitive and emotional status according to the EQoL-VAS category
Variable All participants
(n = 2255)
Group A Low EQoL-VAS
0–50 (n = 487)
Group B Intermediate
EQoL-VAS 51–75 (n = 784)
Group C High EQoL-VAS
76–100 (n = 984)
p-value post hoc
ADL dependent or intensive
assistance > = 1
107 (4.8) 50 (10.3) 33 (4.2) 24 (2.4) < 0.001 a vs. b
a vs. c
b vs c
IADL dependent or intensive
assistance > = 1
993 (44.1) 251 (51.9) 329 (42.0) 413 (42.0) < 0.001 a vs. b
a vs. c
b vs. c
SPPB total score (avarge ± SD) 9 (4) 7 (6) 9 (4) 10 (3) < 0.001 a vs b
a vs c
SPPB Balance score
Held SBS < 10 s and held 10 s
SBS but unable ST as severe
balance limitation
432 (20.1) 151 (34.0) 148 (20.0) 133 (13.8) < 0.001 a vs. b
Moderate limitation Held ST for
10 s und held FT till 9 s.
410 (19.1) 99 (22.3) 143 (19.3) 168 (17.4)
No limitation: hold FT for 10 s. 1307 (60.8) 194 (43.7) 450 (60.7) 663 (68.8) a vs. c
b vs. c
SPPB gait score
< 4.82 s 1138 (50.5) 157 (32.2) 372 (47.4) 609 (61.9) < 0.001 a vs. b
4.82–8.7 s 902 (40.0) 224 (46.0) 348 (44.4) 330 (33.5) a vs. c
> 8.70 s and Unable 215 (9.5) 106 (21.8) 64 (8.2) 45 (4.6) b vs. c
5-sit to stand score
≤ 11.19 s 654 (32.2) 62 (16.5) 222 (31.2) 370 (39.2) < 0.001 a vs. b
11.20–16.69 s 924 (45.5) 163 (43.4) 318 (44.7) 443 (46.9) a vs. c
> 16.70 s and > 60 s or unable 454 (22.3) 151 (40.2) 171 (24.1) 132 (14.0) b vs. c
Hand grip strength (avarge ± SD) 21.0 (12.8) 19.4 (8.3) 22.9 (9.3) 24.1 (9.2) < 0.001 a vs. b
a vs. c
b vs. c
GDS score (avarge ± SD) 2 (3) 4 (4) 2 (3) 1 (3) < 0.001 a vs. b
a vs. c
GDS > 5 316 (14.0) 152 (31.2) 104 (13.3) 60 (6.1) < 0.001 a vs. b
a vs. c
b vs. c
MMSE score (avarge ± SD) 29 (3) 28 (4) 29 (3) 29 (3) < 0.001 a vs. b
a vs. c
MMSE < 24 159 (7.1) 50 (10.3) 46 (5.9) 63 (6.4) 0.007 a vs. b
a vs. c
b vs. c
Fall at the past 12 months 746 (33.1) 207 (42.5) 267 (34.1) 272 (27.6) < 0.001 a vs. b
a vs. c
b vs. c
NOTE. Values are mean ± SD for continuous normal distributions, n (%) for categorical variables, and median (interquartile range) for not normal distributions
Abbreviations: NS, not significance; ADL, activities of daily living; GDS, Geriatric Depression Scale; iADL, instrumental activities of daily living; MMSE, Mini-Mental
State Examination; SPPB, Short Physical performance Battery
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obstructive pulmonary disease), are known to be major
determinant of CKD or highly prevalent comorbidities
among older patients with CKD [49, 50]. Diabetes,
hypertension and chronic obstructive pulmonary disease
were also found associated with QoL decline in dialysis
patients [51–53], and our findings are consistent with
the hypothesis that these comorbidities may negatively
affect QoL even among older people with less severe de-
grees of CKD. On the other hand, diabetic patients
maintaining high level of physical activity and exercise
were exhibited better QoL [54]. Finally, CIRS was found
associated with QoL in community-dwelling older adults
[55], as was polypharmacy [56]. Thus, our findings that
the addition of these variables to the multivariable
models may blunt the association between CKD and
QoL further strengthen their role as important correlates
of QoL among older people and suggests that the impact
of CKD on QoL may be at least partly mediated by risk
factors typically observed among older people.
Limitations of the present study deserve to be men-
tioned. The cross-sectional design does not allow to de-
rive causal relationships between CKD and QoL.
However, the ongoing collection of prospective data in
the context of the SCOPE study is expected to provide
further insight in this topic. Additionally, we enrolled a
population of relatively healthy older community-
dwelling volunteer, thus prone to volunteer bias, which
may reduce generalizability of the present finding to the
general older population. Finally, only creatinine-based
eGFR was used as a measure of kidney function in our
study, and recent evidence suggests that using different
biomarkers (e.g. cystatin C) may yield different results
[42]. As for strength, we had the opportunity to
investigate the association between CKD and QoL after
adjusting for several important confounders thanks to
the comprehensive assessment carried out during the
study visits.
Conclusions
Our study shows that in older adults self-perceived QoL
is multifactorial and influenced by medical, emotional,
functional and social conditions. We observed a signifi-
cant association of CKD stages 3a, 3b and 4 with QoL.
Such association was confirmed after adjusting for socio-
demographic and clinical factors. Efforts should be made
to decrease the negative effects of potentially modifiable
factors, such as physical performance, and to better
manage comorbidities. Further longitudinal studies are
need to clarify whether targeting patients with early
stages of CKD may help to prevent QoL decline.
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